跳至主要内容
临床试验/NCT00254020
NCT00254020已完成4 期

The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression

Sunnybrook Health Sciences Centre10 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2005年6月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
138
试验地点
10
主要终点
Centre for Epidemiological Studies-Depression Scale (CES-D)

研究概览

简要总结

Depression is a common and often serious problem occurring in stroke patients. Inflammatory hormones, known as cytokines, are stimulated by an activated immune system and sometimes become active following a stroke. They may be responsible for altering levels of key neurotransmitters and their metabolites in the blood and brain of stroke patients. The investigators' objective is to examine whether increased cytokine activity following a stroke may be the cause of an increased presence or severity of depression or cognitive impairment among stroke patients, as a result of tryptophan depletion and/or kynurenine activation. They are recruiting patients within one month of their strokes and measuring levels of key markers in their blood. Patients are assessed for the presence of depressive and/or cognitive symptoms and treated with an antidepressant if needed. The investigators expect to show that cytokine activation is related to depression and/or cognitive impairment among stroke patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years
  • Gender: male or female
  • Language: speaks and understands English
  • Clinical diagnosis of stroke according to World Health Organization MONICA Project and recent (< 3 months) cerebral infarctions
  • Written, informed consent
  • Depressed group only: diagnosis of a major depressive episode according to the depression module of the Structured Clinical Interview for the DSM-IV (SCID-IV)

排除标准

  • Subarachnoid hemorrhage
  • Intracranial hemorrhage
  • Significant acute medical illness including: drug overdose, severely disturbed liver, kidney or lung function, anemia, hypothyroidism, or uncontrolled diabetes
  • Significant acute neurologic illness including: impaired consciousness, Parkinson's disease, Huntington's chorea, progressive supranuclear paralysis, brain tumor, subdural hematoma, multiple sclerosis, hydrocephalus, Binswanger's disease, or severe aphasia
  • Presence of a premorbid Axis I psychiatric diagnosis (eg. schizophrenia, bipolar disorder)
  • Depressed group only: contraindications to receiving treatment with citalopram (including previous nonresponse) or serious risk of suicide

结局指标

主要结局

Centre for Epidemiological Studies-Depression Scale (CES-D)

时间窗: Baseline, 6 weeks, 12 weeks

Mini Mental State Examination (MMSE)

时间窗: Baseline, 6 weeks, 12 weeks

NINCDS-CSN Vascular Cognitive Impairment Battery

时间窗: Baseline, 6 weeks, 12 weeks

次要结局

  • NIH Stroke Scale(Baseline, 6 weeks, 12 weeks)
  • Modified Rankin Scale (mRS)(Baseline, 6 weeks, 12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验